NicaraguaTuberculosis profile
Population  2014 6 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.21 (0.16–0.26) 3.4 (2.7–4.3)
Mortality (HIV+TB only) 0.022 (0.017–0.028) 0.37 (0.28–0.47)
Prevalence  (includes HIV+TB) 4.5 (2–7.9) 74 (33–132)
Incidence  (includes HIV+TB) 3.5 (3.2–3.8) 58 (53–63)
Incidence (HIV+TB only) 0.14 (0.11–0.17) 2.3 (1.8–2.8)
         
Case detection, all forms (%) 76 (70–82)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0.63 (0.08–2.2) 11 (6.2–17)
MDR-TB cases among notified pulmonary
TB cases
14 (2–48) 22 (13–35)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 1 447   130
Pulmonary, clinically diagnosed 717   0
Extrapulmonary 338   0
       
Total new and relapse 2 632    
Previously treated, excluding relapses 77    
Total cases notified 2 709    
Among 1 447 new cases:
29 (2%) cases aged under 15 years; male:female ratio: 1.3
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 11 (<1%) 55 (27%) 55
Laboratory-confirmed RR-/MDR-TB cases     18
Patients started on MDR-TB treatment ***     20
TB/HIV 2014 Number (%)
TB patients with known HIV status 2 185 (81)
HIV-positive TB patients    
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 78  
HIV-positive people screened for TB 80  
HIV-positive people provided with IPT 130  
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (84) 1 438
Previously treated cases registered in 2013 (69) 72
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (90) 10
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 3.7
Culture (per 5 million population) 2.5
Drug susceptibility testing (per 5 million population) 0.8
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 4.3
% Funded domestically <1%
% Funded internationally 54%
% Unfunded 45%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-08-25 Data: www.who.int/tb/data